FORMULIERUNG FÜR ANTI-ALPHA4BETA7-ANTIKÖRPER

European patent · EP4403579 · In force

Register entry

Publication number
EP4403579
Application number
EP24167554
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 2, 2012
Published
Jul 24, 2024
Granted
Dec 10, 2025
Protection ends at the latest
May 1, 2032
Next annual fee due
May 31, 2027
IPC classes
A61K 39/395 (2006.01)
A61K 47/12 (2006.01)
A61K 47/14 (2017.01)
A61K 47/18 (2017.01)
A61K 47/26 (2006.01)
A61K 9/00 (2006.01)
A61P 1/00 (2006.01)
A61P 1/04 (2006.01)
A61P 1/16 (2006.01)
A61P 1/18 (2006.01)
A61P 3/10 (2006.01)
A61P 29/00 (2006.01)
A61P 31/18 (2006.01)
A61P 37/06 (2006.01)
A61P 43/00 (2006.01)
Priority
US 201161481522 P 02.05.2011
US 201161544054 P 06.10.2011
Divided from
EP17180247
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Vedolizumab

C04403579/01 · Medicine · Application · Protection from May 2, 2032 to Oct 15, 2035

Authorisation 67534 (Swissmedic, Oct 16, 2020) · Authorisation 67537 (Swissmedic, Oct 16, 2020)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 23, 2026

    Change

    Published in Swissreg on 23.09.2026

  2. Sep 23, 2026

    Change

    Published in Swissreg on 23.09.2026

  3. Sep 23, 2026

    Change

    Published in Swissreg on 23.09.2026

  4. Sep 16, 2026

    Change

    Published in Swissreg on 16.09.2026

  5. Sep 16, 2026

    Change

    Published in Swissreg on 16.09.2026

  6. Sep 16, 2026

    Change

    Published in Swissreg on 16.09.2026

  7. Sep 16, 2026

    Change

    Published in Swissreg on 16.09.2026

  8. Jun 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.05.2026 → 31.05.2027

    Published in Swissreg on 01.06.2026

2 earlier entries
  1. Dec 10, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 10.12.2025

  2. Dec 10, 2025

    Agent entered

    Representative
    Stolmár & Partner Intellectual Property S.à.r.l., Bahnhofstrasse 11, 6210 Sursee

    Published in Swissreg on 10.12.2025

Parties

Holder

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street, Cambridge, MA 02139, US

Agent

Stolmár & Partner Intellectual Property S.à.r.l.

Bahnhofstrasse 11, 6210 Sursee

Inventor

DILUZIO, Willow

Gloucester MA, 01930, US

NGUYEN, Phuong M.

Cambridge, MA, 02141, US

VARGA, Csanad M.

Newton, MA, 02459, US

PALANIAPPAN, Vaithianathan

Andover, MA, 01810, US

BROWN, Jason

Burlington, MA, 01803, US

FOX, Irving H.

Dedham, MA, 02026, US

SCHOLZ, Catherine

North Reading, MA, 01864, US

JENKINS, Erica Helen

Cottenham, Cambridgeshire, CB24 8RB, GB

ROSARIO, Maria

Mystic, CT, 06355, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.